Opioid use disorder

Pinnacle Treatment Centers Expands Services with the Opening of Front Royal, Virginia Location

Retrieved on: 
Monday, July 31, 2023
Mental Health, Hospitals, Health, Pharmaceutical, Managed Care, Methadone, PTC, Opioid use disorder, The Sundays, Employment, Residential treatment center, Environment, Patient, Family therapy, Pinnacle, Substance abuse, Nursing, Hospital

Pinnacle Treatment Centers (PTC) , a leading provider of comprehensive substance abuse treatment services, is pleased to announce the opening of its newest location in Front Royal, Virginia.

Key Points: 
  • Pinnacle Treatment Centers (PTC) , a leading provider of comprehensive substance abuse treatment services, is pleased to announce the opening of its newest location in Front Royal, Virginia.
  • With a commitment to delivering personalized and evidence-based care, Pinnacle Treatment Centers aims to make a positive impact on individuals struggling with addiction in the local community.
  • Situated in the picturesque town of Front Royal, Front Royal Treatment Center will provide a wide range of services to address the unique needs of each patient.
  • To learn more about Front Royal Treatment Center and the services provided, please visit their website .

Opioid Use Disorder (OUD) Epidemiology Forecast 2023-2032: Disease Burden, Demographic Insights, Severity Impact, and Factors Influencing Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, July 28, 2023
Health, Other Health, Growth, EU4, Opioid use disorder, United Kingdom, Ageing, Drug, OUD, Mental health, Vaccine, Health care, Nursing, Epidemiology

Opioid Use Disorder (OUD) Market Research: A Comprehensive Analysis of Epidemiology and Growth Projections in Key Regions

Key Points: 
  • Opioid Use Disorder (OUD) Market Research: A Comprehensive Analysis of Epidemiology and Growth Projections in Key Regions
    Discover the latest market insights on Opioid Use Disorder (OUD) with this comprehensive market research report.
  • Opioid Use Disorder (OUD) Burden: Learn about the chronic use of opioids causing distress, overpowering desire, increased tolerance, and withdrawal syndrome.
  • Disease Burden: Understand the risks and burdens of Opioid Use Disorder (OUD) and growth opportunities in the 7MM regions.
  • Unlock crucial market data with this Opioid Use Disorder (OUD) market research report, providing valuable insights for informed decision-making.

Acadia Healthcare Reports Second Quarter 2023 Results and Raises 2023 Guidance

Retrieved on: 
Thursday, July 27, 2023
Nursing, Mental Health, Health, Infectious Diseases, Hospitals, Other Health, Managed Care, Joint Ventures, Economy of Salt Lake City, IOP, Partnership, Depression, Stony Point Center, Hospital, Nebraska Methodist Health System, Bed, Anxiety, Economy, Opioid use disorder, Coronavirus, Intensive outpatient program, Betty Ford Center, Kaiser Foundation, PHP, United States Census Bureau, Partial, Patient, Growth, Economic security, Mental health, Cryptocurrency, Pharmaceutical industry, Management

Acadia Healthcare Company, Inc. (“Acadia”) (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Acadia Healthcare Company, Inc. (“Acadia”) (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2023.
  • Chris Hunter, Chief Executive Officer of Acadia, remarked, “Acadia delivered strong financial and operating results for the second quarter of 2023, as we continued to see robust demand across all business lines.
  • We continue to see stability with sequential improvement in our labor trends for the second quarter of 2023 that we expect will continue to improve into the second half of the year.
  • “Our results to date and continued momentum in our business led us to increase our financial guidance for the full year.

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

Retrieved on: 
Thursday, July 27, 2023
Agreement, Employment, Sale, Opioid use disorder, Delaware General Corporation Law, SAN, Itch, Nalmefene, Proneura prolongata, Pharmaceutical industry, Titan Pharmaceuticals, Buprenorphine, Titan

SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology.

Key Points: 
  • SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology.
  • Under the terms of the Agreement, Fedson will purchase the ProNeura assets from Titan for an upfront purchase price of $2 million ($1 million at closing, $1 million to be held in escrow pending completion of certain conditions) with potential milestone payments to Titan of up to $50 million on future net sales of the products.
  • Titan would also receive single digit royalties on future net sales of the products.
  • “We are pleased to announce the sale of these potentially lifesaving assets to Fedson,” stated David E. Lazar, Chief Executive Officer of Titan Pharmaceuticals.

Bicycle Health Doctors Fly to Alabama for a Second Year to Ensure Opioid Treatment Continuity for Patients

Retrieved on: 
Tuesday, July 25, 2023
Telehealth, Mouding County, Face, Urine, Buprenorphine, Act, Opioid use disorder, Ground substance, Prescription, OUD, Social stigma, Bicycle, Addiction medicine, DEA, Patient, Transport, Safety, Pharmaceutical industry, Health insurance, Nursing

2022-302 , which prohibited clinicians from writing prescriptions for controlled substances and other medications via telemedicine without an in-person visit.

Key Points: 
  • 2022-302 , which prohibited clinicians from writing prescriptions for controlled substances and other medications via telemedicine without an in-person visit.
  • This decision left over 500 Bicycle Health patients who were utilizing medications for opioid use disorder (MOUD) – such as buprenorphine – scrambling to find in-person care options or otherwise face abandoning the treatment plan they had built via Bicycle Health.
  • This year, Bicycle Health returned once again to Alabama to renew access for 162 established patients who were still unable to find a local Alabama provider.
  • Bicycle Health’s team successfully completed in-person evaluations with 98.8% of these patients over the course of 3 days.

Partnership helping Hoosiers with Opioid Use Disorder outperforms peers

Retrieved on: 
Tuesday, July 25, 2023
Mental Health, Health, Other Health, Managed Care, General Health, Pharmaceutical, Biotechnology, Medicaid, Partnership, Housing, OUD, Opioid use disorder, McLaren Health Care Corporation, Drug, Transport, SVP, Hoosier, Pharmaceutical industry, Health insurance, Nursing, Management

Three years into a partnership to provide health services for 2,500 Hoosiers with Opioid Use Disorder (OUD), MDwise, part of Grand Blanc, Mich.-based McLaren Health Care, and Groups Recover Together have significantly outpaced national success measures.

Key Points: 
  • Three years into a partnership to provide health services for 2,500 Hoosiers with Opioid Use Disorder (OUD), MDwise, part of Grand Blanc, Mich.-based McLaren Health Care, and Groups Recover Together have significantly outpaced national success measures.
  • Claims data for 2,500 MDwise members with OUD was analyzed by CWH Advisors, an independent healthcare management consulting firm.
  • (Six-month retention is a key clinical benchmark in substance use disorder because it is closely tied to lower rates of relapse and overdose.)
  • The total cost of care for members was $443 less per member per month compared to standard medication-only OUD treatment.

AliveCor and Thomas Jefferson University Hospital Partner to Evaluate KardiaMobile 6L for QT Prolongation Screening in Patients Treated for Opioid Use Disorder

Retrieved on: 
Thursday, July 20, 2023
Partnership, Senior, Opioid use disorder, ECG, NARP, Associate, QT interval, DO, MD, Patient, Guideline, Thomas Jefferson University Hospital, Methadone, Alivecor, FDA, Pharmaceutical industry, Medical device

MOUNTAIN VIEW, Calif., July 20, 2023 /PRNewswire/ -- AliveCor, the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced a partnership with the Jefferson Narcotic Addiction Rehabilitation Program (NARP) and Thomas Jefferson University Hospital in Philadelphia to evaluate the benefits of QTc monitoring with KardiaMobile 6L for patients receiving methadone maintenance therapy for opioid use disorder.

Key Points: 
  • MOUNTAIN VIEW, Calif., July 20, 2023 /PRNewswire/ -- AliveCor , the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced a partnership with the Jefferson Narcotic Addiction Rehabilitation Program (NARP) and Thomas Jefferson University Hospital in Philadelphia to evaluate the benefits of QTc monitoring with KardiaMobile 6L for patients receiving methadone maintenance therapy for opioid use disorder.
  • In the six-month pilot study, healthcare professionals will use KardiaMobile 6L, the only medical-grade, six-lead personal ECG device that is FDA-cleared to measure QTc intervals, to detect QT prolongation, a potentially dangerous side effect associated with certain medications like methadone.
  • "We are excited to partner with Thomas Jefferson University Hospital on this important study that will illuminate the benefits of real-time QTc interval monitoring with KardiaMobile 6L on patients' outcomes and their treatment experience," said Patricia Baran, Senior Vice President, Enterprise North America & Biopharma Worldwide.
  • "We look forward to assessing how efficient QTc monitoring with KardiaMobile 6L increases compliance with guideline recommendations, improves the patient experience, enhances treatment, and allows for interdepartmental collaboration," said Daniel Frisch, MD, Associate Professor of Medicine Electrophysiology Section, Thomas Jefferson University Hospital.

BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder

Retrieved on: 
Tuesday, July 18, 2023
PK, Volunteering, Condition, NCT, Addiction, Initiative, Opioid use disorder, United States drug overdose death rates and totals over time, OTCQB, OUD, Trial of the century, Development, Plasma protein binding, Clinical trial, Patient, Partnership to End Addiction, Collection, Cooperative, NIDA, Pain management, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RFA, NIH, Food, Safety, Substance abuse, Pharmaceutical industry, Naltrexone, Drug overdose

Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.

Key Points: 
  • Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.
  • Based on these results, we have submitted for fast track designation and we are preparing to also apply for expanded access.
  • Typically, the FDA responds to fast track designation requests within 60 days or less.
  • Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.

Myths about will power and moral weakness keep people with opioid use disorder from receiving effective medications like methadone, buprenorphine and naltrexone

Retrieved on: 
Thursday, July 13, 2023
Maintenance, Methadone, Failure, Nicotine, Bureau of Medical Services (U.S. Department of State), Diabetes, Friends, Buprenorphine, Office of Inspector General, U.S. Department of Health and Human Services, Opioid use disorder, Research, Medicine, Naltrexone, Caffeine, Heroin, Death, Morphine, Risk, Euphoria, Drug, Weaning, Family, Medication, Dentistry, Birth control, Pharmaceutical industry

Methadone and buprenorphine prevent intense cravings and other symptoms of withdrawal, while naltrexone works by blocking the effects of opioids.

Key Points: 
  • Methadone and buprenorphine prevent intense cravings and other symptoms of withdrawal, while naltrexone works by blocking the effects of opioids.
  • We asked what they thought about using medication to treat opioid use disorder.
  • Across all four groups, we heard three myths about using medication for opioid use disorder.

Medication isn’t trading one drug for another

    • Many of our participants expressed the belief that using medication is the same as using opioids to get high.
    • This misperception is likely rooted in the outdated idea that recovery is defined by total abstinence from all substances, except perhaps caffeine and nicotine.

Medication is an important part of long-term recovery

    • A community member we spoke with said, “It’s a way of weaning them off everything.
    • Guidelines from the U.S. Department of Health and Human Services discourage rapid tapers and affirm that long-term use is the best way to prevent relapse, overdose and death.

Long-term treatment counts as success

    • Many of our study participants voiced the belief that long-term use of medication means the treatment did not work.
    • Just as those with high blood pressure or diabetes may need to remain on medications for the long term, so might some people with opioid use disorder.
    • Keeping people in treatment and alive through use of medications is treatment success, not failure.
    • The latest data from the U.S. Centers for Disease Control and Prevention estimates nearly 83,000 deaths in 2022 involved opioids.

HermesPR Drafts Shelley Risk as General Manager + Executive Vice President

Retrieved on: 
Wednesday, July 12, 2023
Medicare Advantage, Medicaid, IPO, Nate, Head, Communication, Opioid use disorder, Medicare, Clover Health, Growth, PR, Risk, Yammer

Risk most recently served as Chief Marketing Officer at Crossroads , a 119-clinic, 9-state medication-assisted treatment provider for those struggling with opioid use disorder.

Key Points: 
  • Risk most recently served as Chief Marketing Officer at Crossroads , a 119-clinic, 9-state medication-assisted treatment provider for those struggling with opioid use disorder.
  • She additionally brings a wealth of in-house and agency PR experience, with stints as Senior Vice President and General Manager at The Bulleit Group and as Director of Communications at Yammer.
  • New HermesPR clients in 2023 include Ophelia , Found , Talkiatry , Hopper Health , Laguna Health and CodaMetrix , among others.
  • I'm immensely proud and deeply motivated to help grow this agency into the market leader it was born to be."